Intra-aortic balloon pump

MedStar Health Celebrates 40th Anniversary of MedSTAR Transport Air Medical Service

Retrieved on: 
Wednesday, June 28, 2023
Devon Hall, Heart, Pentagon, Assistive technology, Additive effect, Accident, Atmosphere, Intra-aortic balloon pump, Professional, COVID-19, ECMO, Health, Finger, Ambulance, Multimedia, MedSTAR, BSN, MedStar Health, Hospital, Publication, MedStar Washington Hospital Center, Patient, MedStar National Rehabilitation Hospital, MedStar Union Memorial Hospital, RN, Nursing care plan, Growth, Hand, Environment, Mid-Atlantic (United States), APRV, Safety, Injury, Nursing, Online shopping, MD

COLUMBIA, Md., June 28, 2023 /PRNewswire/ -- MedStar Health is honoring the groundbreaking and enduring legacy of MedSTAR Transport, which first launched its life-saving air medevac services 40 years ago.

Key Points: 
  • "It's actually a good example of how MedSTAR Transport is more than just ambulances and helicopters," Dr. Drass said.
  • "As the medical director for our air and ground teams, I'm thrilled to be a part of this critical service that continues to grow with the full support of MedStar Health to help patients receive the care they need when they need it," said MedSTAR Transport Medical Director J. Matthew Sasser, MD .
  • "Long before I started working for MedStar Health, I called on MedSTAR Transport often to transport critical patients who needed a higher level of care than was offered at my hospitals.
  • In addition to MedStar Washington Hospital Center and area community hospitals, MedStar Health hospitals with helipads where MedSTAR Transport can land and take off with patients include:
    Transferring patients proved critically important at the height of the COVID-19 pandemic, as MedStar Health relied on MedSTAR Transport — which saw a 40% increase in transport volume — to distribute severely ill patients across the health system.

Biolog-id Partners With AirMed to Help Enhance Visibility, Availability, and Traceability of Life-saving Blood Components

Retrieved on: 
Wednesday, June 16, 2021
Stem cells, Biotechnology, Pharmaceutical, Oncology, Health, Medical devices, Clinical trials, Other Health, Health care, Medicine, Health, Emergency medical responders, AirMed, Mythological cycle, Tuatha Dé Danann, AirMed International, AirMed, Flight paramedic, Intra-aortic balloon pump, Paramedic

Biolog-ids blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases.

Key Points: 
  • Biolog-ids blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases.
  • We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation, said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed.
  • As a former firefighter I am particularly excited about our technology supporting the important mission of the courageous men and women at AirMed.
  • We use the most state-of-the-art equipment available, which includes digital capnography, invasive line management, and intra-aortic balloon pumps for transport.

Study of 21,848 High-Risk PCI Patients Demonstrates Lower Risk of Death and Complications in Patients who Receive PVADs (Impella)

Retrieved on: 
Wednesday, March 4, 2020
Medical devices, FDA, Health, Clinical trials, Cardiology, Biotechnology, Medicine, Interventional cardiology, Cardiology, Medical specialties, Medical devices, Medical technology, Prosthetics, Impella, Percutaneous coronary intervention, Protected percutaneous coronary intervention, Intra-aortic balloon pump, Ventricular assist device

A study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with percutaneous ventricular assist devices (PVADs), including Impella , demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with intra-aortic balloon pumps (IABPs).

Key Points: 
  • A study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with percutaneous ventricular assist devices (PVADs), including Impella , demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with intra-aortic balloon pumps (IABPs).
  • The study, by Al-khadra, et al., published in the February 15, 2020 print edition of Catheterization & Cardiovascular Interventions .
  • View the full release here: https://www.businesswire.com/news/home/20200304005182/en/
    In the analysis, the PVAD cohort was significantly sicker than the IABP cohort.
  • publication also noted that PVAD patients had a shorter length of stay than IABP patients (4 days vs. 5 days p= <.001>

First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness

Retrieved on: 
Monday, December 16, 2019
FDA, General Health, Health, Medical devices, Medicine, Cardiology, Medical specialties, Circulatory system, Interventional cardiology, Medical devices, Prosthetics, Medical emergencies, Impella, Intra-aortic balloon pump, Randomized controlled trial, Myocardial infarction

The first patient in the multi-center trial was enrolled at Spectrum Health in Grand Rapids, Michigan, by Kevin Wolschleger, MD.

Key Points: 
  • The first patient in the multi-center trial was enrolled at Spectrum Health in Grand Rapids, Michigan, by Kevin Wolschleger, MD.
  • View the full release here: https://www.businesswire.com/news/home/20191216005332/en/
    The Impella CP heart pump will be used in the STEMI DTU randomized controlled trial, which will study unloading prior to reperfusion as a therapy to reduce heart failure risk.
  • The FDA granted Impella its highest level of regulatory approval based on the PROTECT II randomized controlled trial and multiple other FDA audited prospective trials that demonstrate Impellas safety and efficacy, compared to the intra-aortic balloon pump (IABP).
  • The STEMI DTU RCT plans to enroll 668 patients undergoing treatment for a STEMI heart attack at up to 60 sites.

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

Retrieved on: 
Thursday, November 14, 2019
Biotechnology, Medical devices, Other Health, Health, Cardiology, Medicine, Medical specialties, Interventional cardiology, Medical devices, Medical technology, Cardiology, Medical emergencies, Impella, Prosthetics, Protected percutaneous coronary intervention, Abiomed, Intra-aortic balloon pump

It demonstrates that Impella use in high-risk PCI (Protected PCI) and cardiogenic shock , when compared to intra-aortic balloon pump (IABP) or other therapies, is associated with improved patient outcomes and reduced costs.

Key Points: 
  • It demonstrates that Impella use in high-risk PCI (Protected PCI) and cardiogenic shock , when compared to intra-aortic balloon pump (IABP) or other therapies, is associated with improved patient outcomes and reduced costs.
  • In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days.
  • Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

PROTECT III Presented at TCT 2019 – Clinical Data Demonstrates Protected PCI with Impella is Associated with Improved Outcomes

Retrieved on: 
Thursday, September 26, 2019
FDA, Health, Medical devices, Clinical trials, Cardiology, Medicine, Interventional cardiology, Medical devices, Medical specialties, Medical technology, Cardiology, Prosthetics, Impella, Protected percutaneous coronary intervention, Abiomed, Myocardial infarction, Intra-aortic balloon pump

View the full release here: https://www.businesswire.com/news/home/20190926005305/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190926005305/en/
    PROTECT III Presented at TCT 2019 Clinical Data Demonstrates Protected PCI with Impella is Associated with Improved Outcomes (Graphic: Business Wire)
    PROTECT III demonstrates a reduction in the primary endpoint of death, stroke, myocardial infarction and repeat procedures at 90 days with Impella -supported Protected PCI , compared to PROTECT II.
  • The PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever FDA study of hemodynamically supported high-risk PCI patients.
  • Yet the 90-day MACCE rate in PROTECT III is lower than the intra-aortic balloon pump (IABP) control arm from PROTECT II.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Percutaneous Mechanical Circulatory Support Devices: Worldwide Analysis & Forecasts 2019-2025 - Projected to Exhibit a CAGR of 12.3%

Retrieved on: 
Wednesday, April 3, 2019
Medical specialties, Medicine, Cardiology, Intensive care medicine, Interventional cardiology, Medical devices, Prosthetics, Cardiogenic shock, Extracorporeal membrane oxygenation, Extracorporeal, Intra-aortic balloon pump, Ventricular assist device

The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017.

Key Points: 
  • The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017.
  • The percutaneous mechanical circulatory support devices are majorly used as a bridge to help patients suffering with cardiogenic shocks and heart failures.
  • Various research studies shows that improvements and experience with percutaneous mechanical circulatory support may offer the prospect of better outcomes.
  • Global percutaneous mechanical circulatory support devices market, based on the product was segmented into intra-aortic balloon pumps, VA-extracorporeal membrane oxygenation (ECMO), and short-term ventricular assist devices.

Global Percutaneous Mechanical Circulatory Support Devices Market Outlook to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2019
Health, Cardiology, Medical devices, Medicine, Medical specialties, Cardiology, Medical technology, Interventional cardiology, Medical devices, Prosthetics, Intensive care medicine, Ventricular assist device, Extracorporeal, Intra-aortic balloon pump, Impella

The "Percutaneous Mechanical Circulatory Support Devices Market to 2025 - Global Analysis and Forecasts by Product, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Mechanical Circulatory Support Devices Market to 2025 - Global Analysis and Forecasts by Product, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017.
  • Global percutaneous mechanical circulatory support devices market, based on the product was segmented into intra-aortic balloon pumps, VA-extracorporeal membrane oxygenation (ECMO), and short-term ventricular assist devices.
  • Therefore, the segment held the largest market share of 42% for the product segment in the percutaneous mechanical circulatory support devices market and is likely to dominate the market in coming forecast period.

The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017

Retrieved on: 
Monday, March 11, 2019
Medicine, Medical specialties, Cardiology, Medical technology, Interventional cardiology, Medical devices, Prosthetics, Intensive care medicine, Extracorporeal membrane oxygenation, Ventricular assist device, Extracorporeal, Intra-aortic balloon pump

The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017.

Key Points: 
  • The global percutaneous mechanical circulatory support devices market is expected to reach US$ 2,977.8 Mn in 2025 from US$ 1,188.2 in 2017.
  • Various research studies shows that improvements and experience with percutaneous mechanical circulatory support may offer the prospect of better outcomes.
  • Global percutaneous mechanical circulatory support devices market, based on the product was segmented into intra-aortic balloon pumps, VA-extracorporeal membrane oxygenation (ECMO), and short-term ventricular assist devices.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Percutaneous Mechanical Circulatory Support Devices market.

North America Heart Pump Devices Market Report 2018: 2016 Historic Data, Base Year of 2017 & Forecasts 2018-2025

Retrieved on: 
Wednesday, October 3, 2018
Cardiology, Medicine, Circulatory system, Anatomy, Ventricular assist device, Artificial heart, Intra-aortic balloon pump, Heart, Pump

North America heart pump devices market is expected to grow with a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Key Points: 
  • North America heart pump devices market is expected to grow with a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
  • On the basis of product the North America heart pump devices market is segmented into ventricular assist devices, intra-aortic balloon pump, total artificial heart (TAH).
  • On the basis of type the North America heart pump devices market is categorized into implantable heart pump devices and extracorporeal heart pump devices.
  • In 2018, implantable heart pump devices are expected to dominate the North America heart pump devices market in the forecast period 2018 to 2025.